Towards patient-specific tumor antigen selection for vaccination

Immunological Reviews

Volumn 188, Issue , 2002, Pages 164-176

  Rammensee, Hans Georg ^a   Weinschenk, Toni ^a   Gouttefangeas, Cécile ^a   Stevanović, Stefan ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; EPITOPE; HLA ANTIGEN; PEPTIDE DERIVATIVE; TUMOR ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; SUBUNIT VACCINE;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNIZATION; LIGAND BINDING; PRIORITY JOURNAL; TUMOR CELL; VACCINATION; ACTIVE IMMUNIZATION; ALGORITHM; ANTIGEN PRESENTATION; B LYMPHOCYTE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FACTUAL DATABASE; HELPER CELL; IMMUNOLOGY; NEOPLASM; PROTEIN MOTIF; REVIEW;

ALGORITHMS; AMINO ACID MOTIFS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; CANCER VACCINES; CLINICAL TRIALS; CYTOTOXICITY, IMMUNOLOGIC; DATABASES, FACTUAL; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY, ACTIVE; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; VACCINES, SUBUNIT;

EID: 0036813201     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2002.18815.x     Document Type: Article

References (128)

1. De Plaen E, et al. Immunogenic (tum-) variants of mouse tumor P815: Cloning of the gene of tum-antigen P91A and identification of the tum- mutation. Proc Natl Acad Sci USA 1988;85:2274-2278.
2. van der Bruggen P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-1647.
3. Jager E, Jager D, Knuth A. Clinical cancer vaccine trials. Curr Opin Immunol 2002;14:178-182.
4. + cytotoxic-T cell responses: Evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 1996;66:470-476.
5. Loeb LA. A mutator phenotype in cancer. Cancer Res 2001;61:3230-3239.
6. Renner C, Kubuschok B, Trumper L, Pfreundschuh M. Clinical approaches to vaccination in oncology. Ann Hematol 2001;80:255-266.
7. Nestle FO, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-332.
8. Ludewig B, Ochsenbein AF, Odermatt B, Paulin D, Hengartner H, Zinkernagel RM. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 2000;191:795-804.
9. Scanlan MJ, et al. Identification of cancer/testis genes by database mining and mRNA expression analysis. Int J Cancer 2002;98:485-492.
10. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001;50:3-15.
11. Jager E, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO- 1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998;187:265-270.
12. Celis E, et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 1994;91:2105-2109.
13. Brossart P, et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 1999;93:4309-4317.
14. + T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 2000;60:4845-4849.
15. Van Bleek GM, Nathenson SG. Isolation of an endogenously processed immunodominant viral peptide from the class I H-2Kb molecule. Nature 1990;348:213-216.
16. Cox AL, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994;264:716-719.
17. Traversari C, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;176:1453-1457.
18. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991;351:290-296.
19. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994;152:163-175.
20. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI data-base for MHC ligands and peptide motifs. Immunogenetics 1999;50:213-219.
21. Nussbaum AK, Kuttler C, Hadeler KP, Rammensee HG, Schild H. PAProC: A prediction algorithm for proteasomal cleavages available on the WWW. Immunogenetics 2001;53:87-94.
22. Schirle M, Weinschenk T, Stevanovic S. Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens. J Immunol Meth 2001;257:1-16.
23. Kessler JH, et al. Efficient identification of novel HLA-A (*) 0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PKAME by proteasome-mediated digestion analysis. J Exp Med 2001;193:73-88.
24. Ayyoub M, et al. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J Immunol 2002;168:1717-1722.
25. Schirle M, et al. Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur J Immunol 2000;30:2216-2225.
26. Pascolo S, et al. A MAGE-AI HLA-A*0201 epitope identified by mass spectrometry. Cancer Res 2001;61:4072-4077.
27. Schmidt W, et al. Cell-free tumor antigen peptide-based cancer vaccines Proc Natl Acad Sci USA 1997;94:3262-3267.
28. Stevanovic S, Schild H. Quantitative aspects of T cell activation - Peptide generation and editing by MHC class I molecules. Semin Immunol 1999;11:375-384.
29. Klein CA, et al. Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol 2002;20:387-392.
30. Pollack JR, et al. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet 1999;23:41-46.
31. Saeterdal I, et al. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci USA 2001;98:13255-13260.
32. Linnebacher M, et al. Frameshift peptide-derived T-cell epitopes: A source of novel tumor-specific antigens. Int J Cancer 2001;93:6-11.
33. Gaudernack G. T cell responses against mutant ras: A basis for novel cancer vaccines. Immunotechnology 1996;2:3-9.
34. Merchant M, Weinberger SR. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 2000;21:1164-1177.
35. Rosty C, et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 2002;62:1868-1875.
36. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999;17:994-999.
37. Turecek F. Mass spectrometry in coupling with affinity capture-release and isotope-coded affinity tags for quantitative protein analysis. J Mass Spectrom 2002;37:1-14.
38. Cahill DJ. Protein and antibody arrays and their medical applications. J Immunol Meth 2001;250:81-91.
39. Le Naour F. Contribution of proteomics to tumor immunology. Proteomics 2001;1:1295-1302.
40. Madoz-Gurpide J, Wang H, Misek DE, Brichory F, Hanash SM. Protein based microarrays: A tool for probing the proteome of cancer cells and tissues. Proteomics 2001;1:1279-1287.
41. Yewdell JW, Anton LC, Bennink JR. Defective ribosomal products (DRiPs): A major source of antigenic peptides for MHC class I molecules? J Immunol 1996;157:1823-1826.
42. Schubert U, Anton LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 2000;404:770-774.
43. Reits EA, Vos JC, Gromme M, Neefjes J. The major substrates for TAP in vivo are derived from newly synthesized proteins. Nature 2000;404:774-778.
44. Yewdell JW, Schubert U, Bennink JR. At the crossroads of cell biology and immunology: DRiPs and other sources of peptide ligands for MHC class I molecules. J Cell Sci 2001;114:845-851.
45. Schild H, Rammensee HG. Perfect use of imperfection. Nature 2000;404:709-710.
46. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995;270:467-470.
47. Lockhart DJ, et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 1996;14:1675-1680.
48. Young AN, et al. Expression profiling of renal epithelial neoplasms: A method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol 2001;158:1639-1651.
49. Takahashi M, et al. Gene expression profiling of clear cell renal cell carcinoma: Gene identification and prognostic classification. Proc Natl Acad Sci USA 2001 98:9754-9759.
50. Boer JM, et al. Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. Genome Res 2001;11:1861-1870.
51. Zammatteo N, et al. DNA microarray to monitor the expression of MAGE-A genes. Clin Chem 2002;48:25-34.
52. Schultz ES, et al. The product on of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. J Exp Med 2002;195:391-399.
53. Morel S, et al. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 2000;12:107-117.
54. Chen W, Norbury CC, Cho Y, Yewdell JW, Bennink JR. Immunoproteasomes shape immunodominance hierarchies of antiviral CD8 (+) T cells at the levels of T cell repertoire and presentation of viral antigens. J Exp Med 2001;193:1319-1326.
55. Toes RE, et al. Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J Exp Med 2001;194:1-12.
56. Hunt DF, et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992;255:1261-1263.
57. Sahin U, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995;92:11810-11813.
58. Tureci O, Sahin U, Pfreundschuh M. Serological analysis of human tumor antigens. molecular definition and implications. Mol Med Today 1997;3:342-349.
59. Lash AE, et al. SAGEmap: A public gene expression resource. Genome Res 2000;10:1051-1060.
60. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial analysis of gene expression. Science 1995;270:484-487.
61. Zhang L, et al. Gene expression profiles in normal and cancer cells. Science 1997;276:1268-1272.
62. Edgar R, Domrachev M, Lash AE. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucl Acids Res 2002;30:207-210.
63. Haverty PM, et al. HugeIndex: A database with visualization tools for high-density oligonucleotide array data from normal human tissues. Nucl Acids Res 2002;30:214-217.
64. Ashburner M, et al. Gene ontology: Tool for the unification of biology. The Gene Ontolology Consortium. Nat Genet 2000;15:25-29.
65. Pruitt KD, Maglott DR. RefSeq and LocusLink: NCBI gene-centered resources. Nud Acids Res 2001;19:137-140.
66. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;411:380-384.
67. + T-cell evolution in vivo: Response to peptide vaccination with Melan-A/MART-1. Int J Cancer 2002;98:376-388.
68. Hunger RE, et al. Successful induction of immune responses against mutant ras m melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant. Exp Dermatol 2001;10:161-167.
69. Slingluff CL Jr, et al. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: Immunologic and clinical outcomes. Clin Cancer Res 2001;7:3012-3024.
70. Chang AE, et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 2002;8:1021-1032.
71. Bennouna J, Hildesheim A, Chikamatsu K, Gooding W, Storkus WJ, Whiteside TL. Application of IL-5 ELISPOT assays to quantification of antigen-specific T helper responses. J Immunol Meth 2002;161:145-156.
72. Kast WM, Brandt RM, Melief CJ. Strict peptide length is not required for the induction of cytotoxic T lymphocyte-mediated antiviral protection by peptide vaccination. Eur J Immunol 1993;21:1189-1192.
73. Amoscato AA, Prenovitz DA, Lotze MT. Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. J Immunol 1998;161:4023-4032.
74. Iezzi G, Karjalainen K, Lanzavecchia A. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 1998;8:89-95.
75. Mattner F, et al. Vaccination with poly-1-arginine as immunostimulant for peptide vaccines: Induction of potent and long-lasting T-cell responses against cancer antigens. Cancer Res 2002;62:1477-1480.
76. Miconnet I, et al. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J Immunol 2002;168:1212-1218.
77. Kowalczyk DW, Ertl HC. Immune responses to DNA vaccines. Cell Mol Life Sci 1999;55:751-770.
78. Heiser A, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate rumors. J Clin Invest 2002;109:409-417.
79. Hoerr I, Obst R, Rammensee HG, Jung G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 2000;30:1-7.
80. Marchand M, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999;80:219-230.
81. Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin Cancer Res 2000;6:1347-1350.
82. Jager E, et al. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. Int J Cancer 2000;86:538-547.
83. Coulie PG, et al. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int J Cancer 1992;50:289-297.
84. + T cells specific for EBV in healthy virus carriers. J Immunol 1999;162:1827-1835.
85. + T cells using an ELISPOT assay. J Immunol Meth 1995;181:45-54.
86. Lewis JJ, et al. Evaluation of CD8 (+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. Int J Cancer 2000;87:391-398.
87. + T cells after vaccination with antigenic peptide. Clin Cancer Res 2001;7:796s-803s.
88. Yamshchikov GV, et al. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. Int J Cancer 2001;92:703-711.
89. Arlen P, et al. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. Cancer Immunol Immunother 2000;49:517-529.
90. Britten CM, Meyer RG, Kreer T, Drexler I, Wolfel T, Herr W. The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8 (+) T lymphocytes in IFN-gamma ELISPOT assays. J Immunol Meth 2002;259:95-110.
91. Scheibenbogen C, et al. Quantitation of antigen-reactive T cells in peripheral blood by IFN-gamma-ELISPOT assay and chromium-release assay: A four-centre comparative trial. J Immunol Meth 2000;244:81-89.
92. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000;96:3102-3108.
93. Pittet MJ, et al. Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: Implications of a novel approach for T cell monitoring in infectious and malignant diseases. J Immunol 2001;166:7634-7640.
94. Altman JD, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996;174:94-96.
95. Lee PP, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999;5:677-685.
96. Dunbar PR, et al. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J Immunol 2000;165:6644-6652.
97. Coulie PG, et al. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA 2001;98:10290-10295.
98. Speiser DE, et al. In vivo activation of melanoma-specific CD8 (+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Eur J Immunol 2002;31:731-741.
99. Dunbar PR, Ogg GS, Chen J, Rust N, van der Bruggen P, Cerundolo V. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. Curr Biol 1998;8:413-416.
100. Kammula US, et al. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J Immunol 1999;163:6867-6875.
101. Elsasser-Beile U, Rindsfuser M, Grussenmeyer T, Schultze-Seemann W, Wetterauer U. Enhanced expression of IFN-gamma mRNA in CD4 (+) or CD8 (+) tumour-infiltrating lymphocytes compared to peripheral lymphocytes in patients with renal cell cancer. Br J Cancer 2000;83:637-641.
102. Lim A, Baron V, Ferradini L, Bonneville M, Kourilsky P, Pannetier C. Combination of MHC-peptide multimer-based T cell sorting with the Immunoscope permits sensitive ex vivo quantitation and follow-up of human CD8 (+) T cell immune responses. J Immunol Meth 2002;261:177-194.
103. Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 1998;16:364-369.
104. Bristol JA, Orsini C, Lindinger P, Thalhamer J, Abrams SI. Identification of a ras oncogene peptide that contains both CD4 (+) and CD8 (+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization. Cell Immunol 2000;205:73-83.
105. + T cells. Cancer Res 2002;62:213-218.
106. Chaux P, et al. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4 (+) T lymphocytes. J Exp Med 1999;189:767-778.
107. + T lymphocytes to recognize melanoma cells. Cancer Immunol Immunother 2001;49:671-678.
108. Romero P, et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998;188:164-1-1650.
109. Haanen JB, et al. In situ detection of virus- and tumor-specific T-cell immunity. Nat Med 2000;6:1056-1060.
110. + cancers. Proc Natl Acad Sci USA 2000;97:12198-12203.
111. Abdel-Wahab Z, et al. A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response. Cancer 1997;80:401-412.
112. Leyland-Jones B. Trastuzumab: Hopes and realities. Lancet Oncol 2002;3:137-144.
113. Wolfel T, et al. A p1 6INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281-1284.
114. Van den Eypde BJ, et al. A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription. J Exp Med 1999;190:1793-1800.
115. Clark RE, et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 2001;98:2887-2893.
116. Skipper JC, et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 1996;183:527-534.
117. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995;87:982-990.
118. Carrel S, Delisle MC, Mach JP. Antibody-dependent cell-mediated cytolysis of human colon carcinoma cells induced by specific antisera against carcinoembryonic antigen. Cancer Res 1977;37:2644-2650.
119. Disis ML, et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994;54:16-20.
120. Karanikas V, et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 1997;100:2783-2792.
121. Cheresh DA, Honsik CJ, Staffileno LK, Jung G, Reisfeld RA. Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis. Proc Natl Acad Sci USA 1985;82:5155-5159.
122. + T cell responses. Eur J Immunol 1996;26:435-443.
123. Gedde-Dahl T III, Spurkland A, Eriksen JA, Thorsby E, Gaudernack G. Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln→Leu61). Int Immunol 1992;4:1331-1337.
124. Takahashi M, et al. Antibody to ras proteins in patients with colon cancer. Clin Cancer Re 1995;1:1071-1077.
125. Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman LA. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 1997;185:833-841.
126. Crawford LV, Pim DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982;30:403-408.
127. Tarpey I, et al. Human cytotoxic T lymphocytes stimulated by endogenously processed human papillomavirus type 11, E7 recognize a peptide containing a HLA-A2 (A*0201) motif. Immunology 1994;81:222-227.
128. Konya J, Dillner J. Immunity to oncogenic human papillomaviruses. Adv Cancer Res 2001;82:205-238.